scholarly journals Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy

2015 ◽  
pp. 1 ◽  
Author(s):  
Baofa Yu ◽  
Yuanfei Lu ◽  
Feng Gao ◽  
Peng Jing ◽  
Wei Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Effect ◽  
Advanced Stages

scholarly journals Decelerated tumor growth due to hypothyroidism with prolongation of survival in a patient with lung adenocarcinoma: a case report

2019 ◽  
Vol 48 (3) ◽  
pp. 030006051988530
Author(s):  
Jia Hou ◽  
Shan-Shan Xiong ◽  
Zhao-Qi Huang ◽  
Xing-Dong Cai
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Tumor Therapy ◽  
Stage Iv ◽  
Small Cell Lung ◽  
Anti Cancer ◽  
Advanced Stages

Lung adenocarcinoma is a form of non-small-cell lung cancer with high mortality in the advanced stages, and is one of the most common histological subtypes of lung cancer in most countries. Prognosis of lung adenocarcinoma is generally poor, with a median survival of 4–13 months. We report a case of unusually prolonged survival of a patient with advanced lung adenocarcinoma complicated by hypothyroidism. A 71-year-old man with stage IV lung adenocarcinoma presented with hypothyroidism. Surprisingly, without any anti-tumor and anti-hypothyroidism therapy, he survived this lung cancer for longer than 2.5 years before his last follow-up visit. Patients with advanced lung adenocarcinoma rarely survive for longer than 2 years, even after therapy. We hypothesize that hypothyroidism is the cause for this discrepancy. Thyroid hormones can promote growth of carcinoma. Therefore, hypothyroidism appears to be beneficial to anti-cancer therapy. We believe that hypothyroidism, as an adverse event commonly occurring in anti-tumor therapy (e.g., an immune checkpoint inhibitor), might not be able to be completely eliminated.

scholarly journals Therapeutic effect and apoptosis mechanism of lung-tonifying and expectorant decoction on lung cancer rats with Qi deficiency and blood stasis

2015 ◽  
Vol 8 (11) ◽  
pp. 983-988 ◽  
Author(s):  
Feng Yuan ◽  
Ying Zhou ◽  
Ying Jiang ◽  
Rui Liu ◽  
Jian-Zhe Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Effect ◽  
Blood Stasis

scholarly journals Metabolomic Profiling in Lung Cancer: A Systematic Review

Metabolites ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 630
Author(s):  
Daniela Madama ◽  
Rosana Martins ◽  
Ana S. Pires ◽  
Maria F. Botelho ◽  
Marco G. Alves ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Added Value ◽  
Metabolomic Profiling ◽  
Significant Burden ◽  
Advanced Stages ◽  
Altered Metabolism ◽  
Metabolic Biomarkers ◽  
Analytical Platforms

Lung cancer continues to be a significant burden worldwide and remains the leading cause of cancer-associated mortality. Two considerable challenges posed by this disease are the diagnosis of 61% of patients in advanced stages and the reduced five-year survival rate of around 4%. Noninvasively collected samples are gaining significant interest as new areas of knowledge are being sought and opened up. Metabolomics is one of these growing areas. In recent years, the use of metabolomics as a resource for the study of lung cancer has been growing. We conducted a systematic review of the literature from the past 10 years in order to identify some metabolites associated with lung cancer. More than 150 metabolites have been associated with lung cancer-altered metabolism. These were detected in different biological samples by different metabolomic analytical platforms. Some of the published results have been consistent, showing the presence/alteration of specific metabolites. However, there is a clear variability due to lack of a full clinical characterization of patients or standardized patients selection. In addition, few published studies have focused on the added value of the metabolomic profile as a means of predicting treatment response for lung cancer. This review reinforces the need for consistent and systematized studies, which will help make it possible to identify metabolic biomarkers and metabolic pathways responsible for the mechanisms that promote tumor progression, relapse and eventually resistance to therapy.

scholarly journals Immunotherapy for Advanced Small Cell Lung Cancer: A Case Report

2021 ◽  
Vol 6 (5) ◽  
Author(s):  
Wang J ◽  
Deng C ◽  
Zhu X ◽  
Zou X ◽  
Wang J
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Malignant Tumors ◽  
Small Cell ◽  
Immune Checkpoints ◽  
Small Cell Lung ◽  
Advanced Stages ◽  
Made In

In recent years, extraordinary achievements have been made in treating tumor immune checkpoints as targets, which significantly contributes to the research and development of novel immunologic drugs and their application in treating malignant tumors. However, few immunologic drugs can be administered to treat Small Cell Lung Cancer (SCLC). Currently, the focus of most clinical studies is placed on treating SCLC with a combination of immunotherapy and chemotherapy, which is relatively expensive and not covered by medical insurance, thus imposing a heavy economic burden on patients. Meanwhile, obvious adverse reactions occur during chemotherapy, which is still unacceptable to many patients and hence has not yet been widely adopted in clinical practice. Therefore, whether immunotherapy alone can help patients with SCLC, improve their quality of life, and prolong their survival time is a topic we will study in the future. In this case, an attempt was made to apply camrelizumab, an immunologic drug, in the treatment of SCLC in advanced stages, and a favorable efficacy was achieved.

Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study

2017 ◽  
Vol 70 (9) ◽  
pp. 803-806 ◽  
Author(s):  
Roberta Sgariglia ◽  
Pasquale Pisapia ◽  
Mariantonia Nacchio ◽  
Caterina De Luca ◽  
Francesco Pepe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Secondary Analysis ◽  
Small Cell ◽  
Parameter Analysis ◽  
Molecular Testing ◽  
Small Cell Lung ◽  
Advanced Stages

In the advanced stages of non-small cell lung cancer (NSCLC), molecular testing is often performed on archival cytological smears. The nCounter system (NanoString Technologies) is a new promising multiplex digital colour-coded barcode technology. However, its feasibility to evaluate the RNA expression of clinical relevant biomarkers on routine cytological smears is still uncertain. To this end, RNA was extracted from 12 NSCLC routine stained cytological smears, and nCounter analysis performed by using a 48-gene panel. Overall, 11/12 (92%) of the smears were adequate for the secondary analysis, fulfilling the quality check parameter analysis of nSolver software. This pilot study shows that RNA nCounter analysis is feasible on routine cytological smears preparing the field for the implementation of this technology in the routine setting.

Lung cancer: prevent or treat?

2021 ◽  
Vol 4 (4) ◽  
pp. 01-02
Author(s):  
Claribel Pazos
Keyword(s):  
Lung Cancer ◽  
Developing Countries ◽  
Population Growth ◽  
Cause Of Death ◽  
Health Problems ◽  
Advanced Stages ◽  
The Absolute ◽  
Growth And Aging ◽  
Made In

Cancer is currently one of the most serious health problems of humanity, it is among the first as a cause of death in developed and developing countries, with a tendency to continue to rise and occupy the absolute first place for the year 2025 also, because its diagnosis is made in advanced stages, it is estimated that its incidence will double by the year 2030 as a result of population growth and aging and that it may affect all ages, even those fetuses.

Abstract 626: Therapeutic effect of HGF inhibitors against HGF-induced EGFR-TKI resistance in lung cancer harboringEGFRmutations

2010 ◽  
Author(s):  
Seiji Yano ◽  
Wei Wang ◽  
Qi Li ◽  
Ivan S. Donev ◽  
Shinji Takeuchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Effect ◽  
Tki Resistance ◽  
Egfr Tki
Sign in / Sign up

Export Citation Format

Share Document